-
Sep 15, 2016
The office of MedPacto, Inc. was relocated to new place with its research center.
-
Sep 09, 2015
Phase I clinical trial dose escalation - 4th cohort
-
Jan 20, 2015
Completion of the second cohort of TEW-7197 and SMC decided to escalate to the next dose.
-
Oct 21, 2014
Safety Monitoring Committee (SMC) reviewed safety of the first cohort of TEW-7197 and decided to escalate to the next dose.
-
Aug 05, 2014
The first dosing of TEW-7197 in a cancer patient in the USA
-
Jul 17, 2014
Clinical trial of TEW-7197 starts its first step.
-
May 19, 2014
MedPacto gets an approval of IND for TEW-7197 from US FDA
-
Apr 03, 2014
MedPacto, Inc. and OncoVenture have submitted IND application to US FDA for Medpacto's oral ALK5 inhibitor, TEW-7197.